Tous Actualités
Suivre
Abonner Stallergenes

Stallergenes

STALLERGENES : 1st Quarter 2010 : Sustained 13% Growth

Antony, France, April 15, 2010 (ots/PRNewswire)

EURm                   2009     09/08     2010     10/09
                       EURm  %Sales Var.% EURm  %Sales Var.%
    Southern Europe    41.8      74    10 46.9      74    12
    (1)
    Other EU countries 12.7      23    36 14.6      23    15
    Other markets       1.7       3     0  1.8       3     8
    SLIT               47.2      84    16 55.0      87    17
    SCIT                6.9      12    11  6.3      10    (8)
    Other products      2.1       4    11  2.0       3    (6)
    Total Q1 sales     56.2     100    15 63.3     100    13
Sales
Consolidated sales for the 1st quarter grew by 13% to EUR 63.3
million (up 15% in 2009). Foreign exchange effects were positive by
EUR 0.3 million.
This growth confirms the supremacy of SLIT over SCIT,
respectively posting growth of 17% and a decline of 8% over the 1st
quarter. SLIT now accounts for 87% of the laboratory's sales.
The analysis by geographic region highlights satisfactory growth
in all markets, with the "Other EU countries" region continuing to
drive Group growth under the effect of the significant increase in
Oralair(R) sales in Germany.
Changes in financial position and significant transactions and
events of the quarter
The financial position improved: cash net of debt was largely
positive at 31 March, whereas it was negative at the same time last
year.
Preliminary results of the Oralair(R) grasses trial in the US
should be obtained and released before the end of April.
Outlook for the current financial year
The good first quarter results confirmed the guidance for
full-year sales growth in excess of 8%, featuring further improvement
in profit margins.
About Stallergenes
Stallergenes is a European biopharmaceutical laboratory
specialising in treatments by immunotherapy for the prevention and
treatment of allergy-related respiratory conditions, such as rhino
conjunctivitis, rhinitis and allergic asthma. Stallergenes is ranked
seventh among French pharmaceutical laboratories. A pioneer and a
leader in immunotherapy treatments by sublingual administration,
Stallergenes dedicates more than 20% (gross) of its sales to its
Research and Development activities, which are primarily directed at
developing a new therapeutic range enabling the provision of
immunotherapy treatments by sublingual tablets.
Stallergenes realised 2009 sales of EUR 193 million, with over
500,000 patients treated with Stallergenes desensitisation products.
Euronext Paris (Compartment B).
    SBF 120 index.
    ISIN code: FR0000065674
    Reuters code: GEN.PA
    Bloomberg code: GEN.FP
For further financial information, please visit our website:
http://www.stallergenes.com

Contact:

CONTACT: Contacts: Albert Saporta, Chairman and CEO,
Tel.+33-1-55-59-20-04, Christian Thiry, Chief Financial Officer,
Tel.+33-1-55-59-20-95, e-mail: investorrelations@stallergenes.fr;
Investor andAnalyst Relations: Lucile de Fraguier, Pavie Finance,
Tel.+33-1-42-15-04-39, e-mail: contact@pavie-finance.com;
Stallergenes PressRelations: Lise Lemonnier, Communication Officer,
Tel. +33-1-55-59-20-96,e-mail: llemonnier@stallergenes.fr

Plus de actualités: Stallergenes
Plus de actualités: Stallergenes
  • 17.03.2010 – 10:32

    /C O R R E C T I O N -- Stallergenes/

    Antony, France, March 17, 2010 (ots/PRNewswire) - In the news release, "STALLERGENES 2009 : Further Profit Margin Growth and Significant Cash Generation Further Profit Margin Growth and Significant Cash Generation:" issued on 16 Mar 2010 19:50 GMT, by Stallergenes Bloomberg:GENP@FP over PR Newswire, we are advised by a representative of the company that in the section headed '2010 outlook' the second paragraph, ...

  • 14.01.2010 – 18:53

    STALLERGENES : Sales Guidance Exceeded : ?193 Million, up 13%

    Antony, France (ots/PRNewswire) - Million EUR 2008 08/07 2009 09/08 MEUR %Sales Var.% MEUR %Sales Var.% Southern Europe (1) 36.4 73 14 42.4 74 16 Other EU countries (2) 11.3 23 17 13.1 23 16 Other markets 2.0 4 45 1.5 3 (25) ...